In the case of SP and its preferential receptor NK1, which participates in the control of pain transmission and vasodilatation of the cerebral dura mater, only one clinical study was conducted to date to analyze the efficacy of NK1 antagonism in migraine, reporting negative results. The gene discussed is TFF2; the disease is migraine disorder.